| Demographic characteristic | Placebo | UMEC 62.5 μg | UMEC 125 μg | Total |
| Subjects | 68 | 69 | 69 | 206 |
| Age years | 62.5±8.72 | 62.3±9.50 | 64.6±7.96 | 63.1±8.77 |
| Sex | ||||
| Female | 26 (38) | 25 (36) | 27 (39) | 78 (38) |
| Male | 42 (62) | 44 (64) | 42 (61) | 128 (62) |
| Ethnicity | ||||
| African American/African heritage | 1 (1) | 1 (1) | 2 (3) | 4 (2) |
| Asian | 8 (12) | 7 (10) | 6 (9) | 21 (10) |
| Japanese/East Asian heritage/Southeast Asian heritage | 8 (12) | 7 (10) | 6 (9) | 21 (10) |
| White | 59 (87) | 61 (88) | 61 (88) | 181 (88) |
| Height cm | 170.3±8.34 | 170.5±9.44 | 169.3±8.92 | 170.0±8.89 |
| Weight kg | 81.53±19.461 | 80.70±24.272 | 73.12±15.381 | 78.44±20.300 |
| BMI kg·m−2 | 27.96±5.509 | 27.58±7.414 | 25.45±4.688 | 26.99±6.055 |
| Current smokers | 36 (53) | 37 (54) | 39 (57) | 112 (54) |
| Smoking pack-year history | 52.3±30.2 | 45.2±21.2 | 47.5±18.6 | 48.3±23.9 |
| Pre-bronchodilator FEV1 mL | 1247±429.9 | 1303±605.9 | 1252±435.7 | 1267±495.1 |
| Post-salbutamol FEV1 mL | 1388±454.7 | 1366±595.7 | 1356±454.4 | 1370±504.0 |
| Post-salbutamol FEV1/FVC | 46.021±10.6635 | 47.971±11.4884 | 48.377±10.5899 | 47.463±10.9179 |
| Post-salbutamol % pred FEV1 | 47.0±13.05 | 44.5±13.99 | 47.9±14.42 | 46.5±13.84 |
| GOLD stage | ||||
| I# | 0 | 0 | 0 | 0 |
| II¶ | 33 (49) | 25 (36) | 34 (49) | 92 (45) |
| III+ | 26 (38) | 30 (43) | 25 (36) | 81 (39) |
| IV§ | 9 (13) | 14 (20) | 10 (14) | 33 (16) |
Data are presented as n, mean±sd or n (%). UMEC: umeclidinium bromide; BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; % pred: % predicted; GOLD: Global Initiative for Obstructive Lung Disease. #: FEV1 ≥80% pred; ¶: FEV1 ≥50 to <80% pred; +: FEV1 ≥30 to <50% pred; §: FEV1 <30% pred.